TY  - JOUR
AU  - Kazimir, Aleksandr
AU  - Götze, Tom
AU  - Murganić, Blagoje
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Hey-Hawkins, Evamarie
PY  - 2024
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/13242
AB  - Raloxifene, a selective oestrogen receptor modulator (SERM), has demonstrated efficacy in the prevention and therapy of oestrogen receptor-positive (ER+) breast cancer, with some degree of effectiveness against triple-negative forms. This suggests the presence of oestrogen receptor-independent pathways in raloxifene-mediated anticancer activity. To enhance the potential of raloxifene against the most aggressive breast cancer cells, hybrid molecules combining the drug with a metal chelator moiety have been developed. In this study, we synthetically modified the structure of raloxifene by incorporating a 2,2′-bipyridine (2,2′-bipy) moiety, resulting in [6-methoxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl]-[4-(2,2′-bipyridin-4′-yl-methoxy)phenyl]methanone (bipyraloxifene). We investigated the cytotoxic activity of both raloxifene and bipyraloxifene against ER+ breast adenocarcinomas, glioblastomas, and a triple-negative breast cancer (TNBC) cell line, elucidating their mode of action against TNBC. Bipyraloxifene maintained a mechanism based on caspase-mediated apoptosis but exhibited significantly higher activity and selectivity compared to the original drug, particularly evident in triple-negative stem-like MDA-MB-231 cells.
T2  - RSC Medicinal Chemistry
T1  - Bipyraloxifene – a modified raloxifene vector against triple-negative breast cancer
DO  - 10.1039/D4MD00051J
ER  - 

@article{
author = "Kazimir, Aleksandr and Götze, Tom and Murganić, Blagoje and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Hey-Hawkins, Evamarie",
year = "2024",
abstract = "Raloxifene, a selective oestrogen receptor modulator (SERM), has demonstrated efficacy in the prevention and therapy of oestrogen receptor-positive (ER+) breast cancer, with some degree of effectiveness against triple-negative forms. This suggests the presence of oestrogen receptor-independent pathways in raloxifene-mediated anticancer activity. To enhance the potential of raloxifene against the most aggressive breast cancer cells, hybrid molecules combining the drug with a metal chelator moiety have been developed. In this study, we synthetically modified the structure of raloxifene by incorporating a 2,2′-bipyridine (2,2′-bipy) moiety, resulting in [6-methoxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl]-[4-(2,2′-bipyridin-4′-yl-methoxy)phenyl]methanone (bipyraloxifene). We investigated the cytotoxic activity of both raloxifene and bipyraloxifene against ER+ breast adenocarcinomas, glioblastomas, and a triple-negative breast cancer (TNBC) cell line, elucidating their mode of action against TNBC. Bipyraloxifene maintained a mechanism based on caspase-mediated apoptosis but exhibited significantly higher activity and selectivity compared to the original drug, particularly evident in triple-negative stem-like MDA-MB-231 cells.",
journal = "RSC Medicinal Chemistry",
title = "Bipyraloxifene – a modified raloxifene vector against triple-negative breast cancer",
doi = "10.1039/D4MD00051J"
}

Kazimir, A., Götze, T., Murganić, B., Mijatović, S., Maksimović-Ivanić, D.,& Hey-Hawkins, E.. (2024). Bipyraloxifene – a modified raloxifene vector against triple-negative breast cancer. in RSC Medicinal Chemistry.
https://doi.org/10.1039/D4MD00051J

Kazimir A, Götze T, Murganić B, Mijatović S, Maksimović-Ivanić D, Hey-Hawkins E. Bipyraloxifene – a modified raloxifene vector against triple-negative breast cancer. in RSC Medicinal Chemistry. 2024;.
doi:10.1039/D4MD00051J .

Kazimir, Aleksandr, Götze, Tom, Murganić, Blagoje, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Hey-Hawkins, Evamarie, "Bipyraloxifene – a modified raloxifene vector against triple-negative breast cancer" in RSC Medicinal Chemistry (2024),
https://doi.org/10.1039/D4MD00051J . .